• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evogene Ltd

    6/17/25 4:01:10 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    6-K 1 zk2533363.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 OF
    THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of June 17, 2025
     
    Commission File Number: 001-36187

    EVOGENE LTD.
      (Translation of Registrant’s Name into English)
     
    13 Gad Feinstein Street, Park Rehovot
    Rehovot 7638517, Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F ☒       Form 40-F ☐


    CONTENTS
     
    Notice, Proxy Statement and Proxy Card for Annual General Meeting of Shareholders
     
     Evogene Ltd. (“Evogene”) hereby publishes a notice of an annual general meeting of shareholders (the “Meeting”), which is scheduled to take place at 3:00 p.m. (Israel time) on Monday, August 11, 2025, at Evogene’s offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.
     
      Shareholders of record at the close of business on Monday, June 23, 2025, are entitled to vote at the Meeting.
     
     Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is the Notice of Annual General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, the required majority for approval of each proposal at the Meeting, the voting procedure and additional general matters related to the Meeting.
     
     Attached as Exhibit 99.2 to this Form 6-K is the Proxy Statement for the Meeting, which describes in greater detail the proposals to be presented at the Meeting, including background information related to the proposals, additional logistical information concerning the required vote and means of voting on the proposals, and general information concerning Evogene’s board of directors and corporate governance.
     
     Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by Evogene to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting.
     
     The contents of Exhibits 99.1, 99.2 and 99.3 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-286197 and 333-259215) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
     
    Exhibits No. 
     
     
    99.1

    Notice for the Annual General Meeting of Evogene Ltd. to be held on August 11, 2025
     

     
    99.2

    Proxy Statement for the Annual General Meeting of Evogene Ltd.
     
     
    99.3

    Proxy Card to be distributed to record shareholders of Evogene Ltd. to cast their vote at the Annual General Meeting of Evogene Ltd.
     
    2

    Signature
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.




    Date: June 17, 2025
    EVOGENE LTD.
    (Registrant)

    By: /s/ Yaron Eldad
    Yaron Eldad
    Chief Financial Officer

     
    3
    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings